Use of an ETEC Proteome Microarray to Evaluate Cross-Reactivity of ETVAX^® Vaccine-Induced IgG Antibodies in Zambian Children.

ABSTRACT: Developing a broadly protective vaccine covering most ETEC variants has been elusive. The most clinically advanced candidate yet is an oral inactivated ETEC vaccine (ETVAX^®). We report on the use of a proteome microarray for the assessment of cross-reactivity of anti-ETVAX^® IgG antibodies against over 4000 ETEC antigens and proteins. We evaluated 40 (pre-and post-vaccination) plasma samples from 20 Zambian children aged 10-23 months that participated in a phase 1 trial investigating the safety, tolerability, and immunogenicity of ETVAX^® adjuvanted with dmLT. Pre-vaccination samples revealed high IgG responses to a variety of ETEC proteins including classical ETEC antigens (CFs and LT) and non-classical antigens. Post-vaccination reactivity to CFA/I, CS3, CS

SUBMITTER: Mubanga C 

PROVIDER: S-EPMC10224314 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature